abhd-5.1 Antibody

Overview of ABHD5 Antibodies

ABHD5 (also known as CGI-58) is a lysophosphatidic acid acyltransferase involved in lipid metabolism, keratinocyte differentiation, and triacylglycerol regulation . Antibodies against ABHD5 are widely used to investigate its role in metabolic disorders, Chanarin-Dorfman syndrome (CDS), and viral assembly mechanisms (e.g., hepatitis C virus) .

Research Applications

ABHD5 antibodies enable:

• Lipid Metabolism Studies: ABHD5 activates PNPLA2 to regulate triacylglycerol storage .

• Viral Pathogenesis: ABHD5 knockdown reduces hepatitis C virus (HCV) assembly and release by disrupting lipid droplet dynamics .

• Genetic Disorders: Mutations in ABHD5 cause CDS, characterized by intracellular lipid accumulation .

Role in HCV Assembly

ABHD5 facilitates HCV virion maturation by mobilizing lipids between lipid droplets and the trans-Golgi network. Silencing ABHD5 reduces extracellular infectivity by 70% .

Therapeutic Targeting

Small-molecule inhibitors (e.g., SR-4995) disrupt ABHD5-PLIN1 interactions, stimulating lipolysis (EC₅₀: 4–7 μM) . These compounds are explored for metabolic syndrome treatments .

Table 2: Antibody Performance in Model Systems

Limitations and Future Directions

Current ABHD5 antibodies show robust reactivity in human and mouse models but lack validation in non-mammalian systems. Future work should address:

• Development of isoform-specific antibodies.

• High-resolution structural studies using cryo-EM.